Ralliant (NYSE:RAL) SVP Karen Bick Sells 5,485 Shares

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 5,485 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total value of $246,825.00. Following the transaction, the senior vice president directly owned 46,756 shares in the company, valued at $2,104,020. This represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ralliant Stock Down 1.4%

NYSE RAL traded down $0.64 during trading on Thursday, hitting $46.36. The company’s stock had a trading volume of 2,098,887 shares, compared to its average volume of 2,052,811. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $57.02. The company has a market cap of $5.18 billion and a PE ratio of 23.65. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. The business’s 50 day simple moving average is $49.18 and its 200-day simple moving average is $46.63.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analysts’ expectations of $543.04 million. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Ralliant’s payout ratio is 10.20%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RAL. Danske Bank A S purchased a new stake in Ralliant in the 4th quarter worth approximately $25,000. Westfuller Advisors LLC acquired a new position in shares of Ralliant in the 3rd quarter valued at $26,000. V Square Quantitative Management LLC purchased a new stake in Ralliant during the fourth quarter worth $26,000. Allworth Financial LP grew its position in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the period. Finally, Palisade Asset Management LLC acquired a new stake in Ralliant during the third quarter valued at $26,000.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $45.00 price target on shares of Ralliant in a research report on Friday, February 6th. Royal Bank Of Canada reduced their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 6th. Barclays dropped their target price on Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Friday, February 6th. Finally, Citigroup dropped their price objective on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.